Joseph Onakewhor obtained his MD and MPH from the University of Benin, Nigeria and M.Sc in human Anatomy for the University of Calabar, Nigeria. He had his residency training at the University of Benin Teaching Hospital(UBTH), and bagged the Fellowship of the West African College of Surgeons (FWACS) in the Faculty of Obstetrics and Gynecology. He was awarded the Fellowship of the International College of Surgeons (FICS) 2004.He also had training at the Institute of Human Virology, University of Maryland, Baltimore and an ISID- sponsored fellowship at the Memorial Sloan Kettering Cancer Center, New York. He is a Professor and Consultant OB-Gyn in in Maternal -Fetal Medicine at UBTH with over thirty five publications in reputable Journals, member of the National Task Team PMTCT of HIV in Nigerian, Focal Point PMTCT, UBTH and Member of two Editorial Boards.


Globally, about 2 billion people have markers of current or past hepatitis (HBV) infection and estimated 350–400 million are chronically afflicted. In Nigeria, 4.3% and 6.8% of pregnant women and partners of infected women respectively are infected. Though, a vertically transmissible and vaccine preventable infection, data on mother-tochild transmission (MTCT) of HBV in Nigeria is scarce. Immunoprophylaxis with immunoglobulin (HBIG) for exposed babies plus a course of 3 vaccinations is expected to produce adequate immune response (antibodies>100mIU/ml) and protection for at least 25 years. We investigated the immunological pattern of HBVinfected mothers and their exposed infants and compared them with HBV-non-exposed babies in a prospective case-control pilot study in a PMTCT program in low-resource setting (LRS). The Nigerian Government/UNICEF provides free to children HBV immunization but HBIG is provided at personal cost that is prohibitive to majority of parents. When exposed infants did not receive HBIG, parents exhibit a lot of anxiety about the potential for their infection. Consequently, we determined if every exposed newborn required standard dose 200iu HBIG in LRS. We compared the pattern of immunological response of infants that received 200iu with those that received 100iu HBIG. All babies received in addition three doses of HBV vaccine. The median period of followed-up was 9 (range 0-15) months. The MTCT rate was zero. However, exposed babies were less likely than their unexposed counterparts to respond to vaccination (p<0.0001; RR 0.055). We advocate large multicenter studies as our findings may elicit policy change beneficial to people from LRS.

Speaker Presentations

Speaker PDFs